NCT06459193View on ClinicalTrials.gov

Trimetazidine Efficacy in Attenuating Paclitaxel-Induced Peripheral Neuropathy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 23, 2024

Primary Completion Date

January 28, 2025

Study Completion Date

March 27, 2025

Conditions
Peripheral Neuropathy Due to Chemotherapy
Interventions
DRUG

Trimetazidine

Trimetazidine 35 mg tab once daily

DRUG

Placebo

Placebo once daily

Trial Locations (1)

61512

Minia Oncology Center, Minya

All Listed Sponsors
lead

Minia University

OTHER

NCT06459193 - Trimetazidine Efficacy in Attenuating Paclitaxel-Induced Peripheral Neuropathy | Biotech Hunter | Biotech Hunter